Vaidya Sane Ayurved Laboratories Private Limited performs research and development in Ayurveda and sells ayurvedic products and medicines through its franchises and clinics. It was founded in 1999 with its headquarters in Pune, Maharashtra. For FY 2020-2021, the company’s total revenue was Rs. 52.28 crore, down 30.57% from the previous financial year. As of 16 June 2022, the company’s market capitalisation was worth Rs. 163 crore.
Vaidya Sane Ayurved Laboratories Limited is listed on the National Stock Exchange with the code MADHAVBAUG. At present, it is not listed on the Bombay Stock Exchange.
Vaidya Sane Ayurved Laboratories Ltd. focuses on using the knowledge of Ayurveda and modern medicine to address the growing trend of non-communicable diseases, such as diabetes and heart diseases. In 2006, the company inaugurated its first Madhavbaug Hospital. At present, the company has two hospitals and 274 clinics across the country. Madhavbaug has developed a strong foothold in non-invasive cardiac care.
On 31 March 2022, the company’s shareholding pattern showed a 66.34% stake with the promoters and a 33.66% stake with the public. As per Vaidya Sane Ayurved Laboratories Ltd.’s balance sheet, the total assets for FY 2021-2022 were worth Rs. 51.74 crore. This value includes current assets worth Rs. 27.22 crore and non-current assets worth Rs. 24.52 crore.
Mr Rohit Madhav Sane is the CEO and managing director of the company, Mr Darshan Shah is the chief financial officer, and Mr Mahesh P Khirsagar, Mr Ratnakar V Rai, Mr Vidyut B Ghag, and Mr Sushrut R Dambal are the directors of the company. The auditors are Vikrant Salunke & Associates.
On 16 June 2022, Vaidya Sane Ayurved Laboratories Limited’s share price closed at Rs. 155.80 on NSE. Since the company is not listed on the Bombay Stock Exchange, one cannot check its price on BSE. The 52-week high for Vaidya Sane’s share price on NSE was Rs. 249.40, and the 52-week low for the share price was Rs. 98.
Vaidya Sane Ayurved Lab Pvt. Ltd.’s peers include Divi’s Laboratories Ltd., Syngene International Ltd., Dishman Carbogen Amcis Ltd., Brooks Laboratories Ltd., Vimta Labs Ltd., Dr Reddys Labs, etc.
Disclaimer- ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: firstname.lastname@example.org. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.